Artykuły w czasopismach na temat „High mobility group phosphoprotein A2”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „High mobility group phosphoprotein A2”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Natarajan, Suchitra, Farhana Begum, Jeonga Gim, Landon Wark, Dana Henderson, James R. Davie, Sabine Hombach-Klonisch i Thomas Klonisch. "High Mobility Group A2 protects cancer cells against telomere dysfunction". Oncotarget 7, nr 11 (18.01.2016): 12761–82. http://dx.doi.org/10.18632/oncotarget.6938.
Pełny tekst źródłaLi, A. Y. J., H. H. Lin, C. Y. Kuo, H. M. Shih, C. C. C. Wang, Y. Yen i D. K. Ann. "High-Mobility Group A2 Protein Modulates hTERT Transcription To Promote Tumorigenesis". Molecular and Cellular Biology 31, nr 13 (2.05.2011): 2605–17. http://dx.doi.org/10.1128/mcb.05447-11.
Pełny tekst źródłaWang, Ya-Dong, Jia-Ding Mao, Jun-Feng Wang i Mao-Qi Xu. "MiR-590 Suppresses Proliferation and Induces Apoptosis in Pancreatic Cancer by Targeting High Mobility Group A2". Technology in Cancer Research & Treatment 19 (1.01.2020): 153303382092814. http://dx.doi.org/10.1177/1533033820928143.
Pełny tekst źródłaHawsawi, Ohuod, Veronica Henderson, Liza J. Burton, Jodi Dougan, Peri Nagappan i Valerie Odero-Marah. "High mobility group A2 (HMGA2) promotes EMT via MAPK pathway in prostate cancer". Biochemical and Biophysical Research Communications 504, nr 1 (wrzesień 2018): 196–202. http://dx.doi.org/10.1016/j.bbrc.2018.08.155.
Pełny tekst źródłaGong, Jian, Yuxiang Wang, Buping Jiang, Bin Xu i Chuanzhen Hu. "Impact of high-mobility-group A2 overexpression on epithelial-mesenchymal transition in pancreatic cancer". Cancer Management and Research Volume 11 (maj 2019): 4075–84. http://dx.doi.org/10.2147/cmar.s199289.
Pełny tekst źródłaCui, Tengjiao, Suzanne Joynt, Victor Morillo, Maria Baez, Zhichun Hua, Xiaotang Wang i Fenfei Leng. "Large Scale Preparation of the Mammalian High Mobility Group Protein A2 for Biophysical Studies". Protein & Peptide Letters 14, nr 1 (1.01.2007): 87–91. http://dx.doi.org/10.2174/092986607779117281.
Pełny tekst źródłaGong, Yan, Xin Jin, Quan-Shun Wang, Shi-Hui Wei, Bao-Ke Hou, Hong-Yang Li, Mao-Nian Zhang i Zhao-Hui Li. "The involvement of high mobility group 1 cytokine and phospholipases A2 in diabetic retinopathy". Lipids in Health and Disease 13, nr 1 (2014): 156. http://dx.doi.org/10.1186/1476-511x-13-156.
Pełny tekst źródłaHeilmann, Thorsten, Florian Vondung, Christoph Borzikowsky, Sandra Krüger, Mohamed Elessawy, Ibrahim Alkatout, Antonia Wenners i in. "Cytoplasmic levels of high mobility group A2 determine survival prognoses in breast cancer patients". International Journal of Biological Markers 35, nr 2 (12.05.2020): 20–28. http://dx.doi.org/10.1177/1724600820917990.
Pełny tekst źródłaBinabaj, Maryam Moradi, Atena Soleimani, Farzad Rahmani, Amir Avan, Majid Khazaei, Hamid Fiuji, Saman Soleimanpour i in. "Prognostic value of high mobility group protein A2 (HMGA2) over-expression in cancer progression". Gene 706 (lipiec 2019): 131–39. http://dx.doi.org/10.1016/j.gene.2019.04.088.
Pełny tekst źródłaPeng, Yi, Jordan Laser, Guizhi Shi, Khush Mittal, Jonathan Melamed, Peng Lee i Jian-Jun Wei. "Antiproliferative Effects by Let-7 Repression of High-Mobility Group A2 in Uterine Leiomyoma". Molecular Cancer Research 6, nr 4 (kwiecień 2008): 663–73. http://dx.doi.org/10.1158/1541-7786.mcr-07-0370.
Pełny tekst źródłaLiu, Zhuoxing, Kunpeng Wu, Zhixiong Yang i Aibing Wu. "High-mobility group A2 overexpression is an unfavorable prognostic biomarker for nasopharyngeal carcinoma patients". Molecular and Cellular Biochemistry 409, nr 1-2 (17.07.2015): 155–62. http://dx.doi.org/10.1007/s11010-015-2521-0.
Pełny tekst źródłaChen, Hwudaurw, Earlphia Sells, Ritu Pandey, Edward R. Abril, Chiu-Hsieh Hsu, Robert S. Krouse, Raymond B. Nagle, Georgios Pampalakis, Georgia Sotiropoulou i Natalia A. Ignatenko. "Kallikrein 6 protease advances colon tumorigenesis via induction of the high mobility group A2 protein". Oncotarget 10, nr 58 (22.10.2019): 6062–78. http://dx.doi.org/10.18632/oncotarget.27153.
Pełny tekst źródłaVenkatesan, Nalini, Mallikarjuna Kandalam, Gunisha Pasricha, Venil Sumantran, Guidalberto Manfioletti, Santa Jeremy Ono, Maddy Ashwin Reddy i Subramanian Krishnakumar. "Expression of High Mobility Group A2 Protein in Retinoblastoma and its Association With Clinicopathologic Features". Journal of Pediatric Hematology/Oncology 31, nr 3 (marzec 2009): 209–14. http://dx.doi.org/10.1097/mph.0b013e318197978d.
Pełny tekst źródłaNie, Dan, Lingping Zhang, Qian Guo i Xiguang Mao. "High mobility group protein A2 overexpression indicates poor prognosis for cancer patients: a meta-analysis". Oncotarget 9, nr 1 (10.12.2017): 1237–47. http://dx.doi.org/10.18632/oncotarget.23085.
Pełny tekst źródłaWei, Chun-Hui. "Effect of silencing of high mobility group A2 gene on gastric cancer MKN-45 cells". World Journal of Gastroenterology 19, nr 8 (2013): 1239. http://dx.doi.org/10.3748/wjg.v19.i8.1239.
Pełny tekst źródłaFusco, Ileana, Deepak Babu, Simona Mellone, Nadia Barizzone, Flavia Prodam, Antonella Fanelli, Ranjit Muniswamy i in. "Variations in the high-mobility group-A2 gene (HMGA2) are associated with idiopathic short stature". Pediatric Research 79, nr 2 (4.11.2015): 258–61. http://dx.doi.org/10.1038/pr.2015.225.
Pełny tekst źródłaWang, Lihui, Weiming Weng, Shuhui Yang, Shasha Yang i Richang Du. "Circle RNA circ_0007331 promotes colorectal carcinoma by targeting miR-205-5p/high-mobility group A2 axis". Bioengineered 13, nr 4 (1.04.2022): 9312–21. http://dx.doi.org/10.1080/21655979.2022.2051857.
Pełny tekst źródłaZhu, Shoukang, Shanming Deng, Qi Ma, Taifang Zhang, Chunling Jia, Degen Zhuo, Falin Yang i in. "MicroRNA-10A* and MicroRNA-21 Modulate Endothelial Progenitor Cell Senescence Via Suppressing High-Mobility Group A2". Circulation Research 112, nr 1 (4.01.2013): 152–64. http://dx.doi.org/10.1161/circresaha.112.280016.
Pełny tekst źródłaBouatia-Naji, Nabila, Marion Marchand, Christine Cavalcanti-Proença, Samia Daghmoun, Emmanuelle Durand, Jean Tichet, Michel Marre, Beverley Balkau, Philippe Froguel i Claire Lévy-Marchal. "Smallness for gestational age interacts with high mobility group A2 gene genetic variation to modulate height". European Journal of Endocrinology 160, nr 4 (kwiecień 2009): 557–60. http://dx.doi.org/10.1530/eje-08-0794.
Pełny tekst źródłaTan, E.-Jean, Kaoru Kahata, Oskar Idås, Sylvie Thuault, Carl-Henrik Heldin i Aristidis Moustakas. "The high mobility group A2 protein epigenetically silences the Cdh1 gene during epithelial-to-mesenchymal transition". Nucleic Acids Research 43, nr 1 (9.12.2014): 162–78. http://dx.doi.org/10.1093/nar/gku1293.
Pełny tekst źródłaBakhidze, E. V., A. V. Malek i A. V. Belyaeva. "The target genes research for diagnosis, therapy and prognosis in cases with ovarian cancer". Journal of Clinical Oncology 25, nr 18_suppl (20.06.2007): 16060. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.16060.
Pełny tekst źródłaLEE, JUNHYUN, SHINJUNG HA, CHAN-KWON JUNG i HAN HONG LEE. "High-mobility-group A2 overexpression provokes a poor prognosis of gastric cancer through the epithelial-mesenchymal transition". International Journal of Oncology 46, nr 6 (1.04.2015): 2431–38. http://dx.doi.org/10.3892/ijo.2015.2947.
Pełny tekst źródłaChung, Jaewook, Xia Zhang, Bruce Collins, Renan B. Sper, Katherine Gleason, Sean Simpson, Sehwon Koh i in. "High mobility group A2 (HMGA2) deficiency in pigs leads to dwarfism, abnormal fetal resource allocation, and cryptorchidism". Proceedings of the National Academy of Sciences 115, nr 21 (7.05.2018): 5420–25. http://dx.doi.org/10.1073/pnas.1721630115.
Pełny tekst źródłaAbe, N., T. Watanabe, Y. Suzuki, N. Matsumoto, T. Masaki, T. Mori, M. Sugiyama, G. Chiappetta, A. Fusco i Y. Atomi. "An increased high-mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue". British Journal of Cancer 89, nr 11 (25.11.2003): 2104–9. http://dx.doi.org/10.1038/sj.bjc.6601391.
Pełny tekst źródłaNatarajan, Suchitra, Thatchawan Thanasupawat, Amy Rommel, Hugo Bergen, Inder Verma, Marc Del Bigio, Marshall Pitz i in. "Targeting oncofetal high mobility group A2 (HMGA2) to increase sensitivity to temozolomide (TMZ) in glioblastoma (GB) cells". Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 41, s2 (październik 2014): S3—S4. http://dx.doi.org/10.1017/cjn.2014.52.
Pełny tekst źródłaKim, Tae Hoen, Ji-ye Song, Hyun Park, Ju-yeon Jeong, A.-young Kwon, Jin Hyung Heo, Haeyoun Kang, Gwangil Kim i Hee Jung An. "miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma". Cancer Letters 356, nr 2 (styczeń 2015): 937–45. http://dx.doi.org/10.1016/j.canlet.2014.11.011.
Pełny tekst źródłaGallivan, Monica V., Laura A. Worfolk, Christina D. Lapuz, Olivia Saqui, Larielyn P. Pan i Jeffrey S. Dlott. "Comparison of High Resolution HPLC with Capillary Zone Electrophoresis in Hemoglobin A2 Measurement." Blood 110, nr 11 (16.11.2007): 3832. http://dx.doi.org/10.1182/blood.v110.11.3832.3832.
Pełny tekst źródłaGaldiero, Francesca, Annunciata Romano, Rosa Pasquinelli, Sandro Pignata, Stefano Greggi, Emilia Vuttariello, Anna Maria Bello i in. "Detection of high mobility group A2 specific mRNA in the plasma of patients affected by epithelial ovarian cancer". Oncotarget 6, nr 22 (12.02.2015): 19328–35. http://dx.doi.org/10.18632/oncotarget.2896.
Pełny tekst źródłaGuo, Xiangjun, Jiaxin Shi, Yan Wen, Mengmeng Li, Qin Li, Xiaomei Li i Jiashu Li. "Increased high-mobility group A2 correlates with lymph node metastasis and prognosis of non-small cell lung cancer". Cancer Biomarkers 21, nr 3 (14.02.2018): 547–55. http://dx.doi.org/10.3233/cbm-170401.
Pełny tekst źródłaLee, Seunghee, Ji-Won Jung, Sang-Bum Park, Kyounghwan Roh, Su Yeon Lee, Ju Han Kim, Soo-Kyung Kang i Kyung-Sun Kang. "Histone deacetylase regulates high mobility group A2-targeting microRNAs in human cord blood-derived multipotent stem cell aging". Cellular and Molecular Life Sciences 68, nr 2 (21.07.2010): 325–36. http://dx.doi.org/10.1007/s00018-010-0457-9.
Pełny tekst źródłaDi Agostino, Silvia, Monica Fedele, Paolo Chieffi, Alfredo Fusco, Pellegrino Rossi, Raffaele Geremia i Claudio Sette. "Phosphorylation of High-Mobility Group Protein A2 by Nek2 Kinase during the First Meiotic Division in Mouse Spermatocytes". Molecular Biology of the Cell 15, nr 3 (marzec 2004): 1224–32. http://dx.doi.org/10.1091/mbc.e03-09-0638.
Pełny tekst źródłaCaron, Leslie, Frédéric Bost, Matthieu Prot, Paul Hofman i Bernard Binétruy. "A new role for the oncogenic high-mobility group A2 transcription factor in myogenesis of embryonic stem cells". Oncogene 24, nr 41 (20.06.2005): 6281–91. http://dx.doi.org/10.1038/sj.onc.1208781.
Pełny tekst źródłaMiao, Yi, Tengjiao Cui, Fenfei Leng i W. David Wilson. "Inhibition of high-mobility-group A2 protein binding to DNA by netropsin: A biosensor-surface plasmon resonance assay". Analytical Biochemistry 374, nr 1 (marzec 2008): 7–15. http://dx.doi.org/10.1016/j.ab.2007.10.023.
Pełny tekst źródłaKalomoiris, Stefanos, Andrew C. Cicchetto, Kinga Lakatos, Jan A. Nolta i Fernando A. Fierro. "Fibroblast Growth Factor 2 Regulates High Mobility Group A2 Expression in Human Bone Marrow-Derived Mesenchymal Stem Cells". Journal of Cellular Biochemistry 117, nr 9 (8.03.2016): 2128–37. http://dx.doi.org/10.1002/jcb.25519.
Pełny tekst źródłaCopley, Michael R., David G. Kent, Claudia Benz, Keegan M. Rowe, Stefan H. Woehrer i Connie J. Eaves. "Evidence That High-Mobility Group A2 (Hmga2) Expression Contributes to the Ontogeny-Dependent Properties of Fetal Hematopoietic Stem Cells." Blood 116, nr 21 (19.11.2010): 2634. http://dx.doi.org/10.1182/blood.v116.21.2634.2634.
Pełny tekst źródłaLin, H. Helen, Ye Xiong, Ye-Shih Ho, Beiyun Zhou, Ha-Van Nguyen, Hongtao Deng, Renee Lee, Yun Yen, Zea Borok i David K. Ann. "Transcriptional regulation by targeted expression of architectural transcription factor high mobility group A2 in salivary glands of transgenic mice". European Journal of Oral Sciences 115, nr 1 (luty 2007): 30–39. http://dx.doi.org/10.1111/j.1600-0722.2007.00421.x.
Pełny tekst źródłaMotoyama, Kazuo, Hiroshi Inoue, Yoshito Nakamura, Hiroyuki Uetake, Kenichi Sugihara i Masaki Mori. "Clinical Significance of High Mobility Group A2 in Human Gastric Cancer and Its Relationship to let-7 MicroRNA Family". Clinical Cancer Research 14, nr 8 (15.04.2008): 2334–40. http://dx.doi.org/10.1158/1078-0432.ccr-07-4667.
Pełny tekst źródłaEl-Hennawi, Diaa El-Din, Mohamed El Tabbakh, Nagwan Sabek, Ashraf Abou-halawa i Amr Fareed. "High Mobility Group A2 (HMGA2) and Matrix Metalloproteinase 12 (MMP12) Genes Expression in Egyptian Patients with Laryngeal Squamous Cell Carcinoma". Egyptian Journal of Ear, Nose, Throat and Allied Sciences 20, nr 2 (1.07.2019): 94–98. http://dx.doi.org/10.21608/ejentas.2019.6403.1056.
Pełny tekst źródłaCampbell, Taaliah, Ohuod Hawsawi, Nathan Bowen i Valerie Odero-Marah. "Abstract 113: Investigating the role of high mobility group a2 (HMGA2) truncated isoform in promoting oxidative stress in PCa cells". Cancer Research 82, nr 12_Supplement (15.06.2022): 113. http://dx.doi.org/10.1158/1538-7445.am2022-113.
Pełny tekst źródłaTan, E.-Jean, Sylvie Thuault, Laia Caja, Tea Carletti, Carl-Henrik Heldin i Aristidis Moustakas. "Regulation of Transcription Factor Twist Expression by the DNA Architectural Protein High Mobility Group A2 during Epithelial-to-Mesenchymal Transition". Journal of Biological Chemistry 287, nr 10 (11.01.2012): 7134–45. http://dx.doi.org/10.1074/jbc.m111.291385.
Pełny tekst źródłaRizzi, Claudio, Palmina Cataldi, Aldo Iop, Miriam Isola, Riccardo Sgarra, Guidalberto Manfioletti i Vincenzo Giancotti. "The expression of the high-mobility group A2 protein in colorectal cancer and surrounding fibroblasts is linked to tumor invasiveness". Human Pathology 44, nr 1 (styczeń 2013): 122–32. http://dx.doi.org/10.1016/j.humpath.2012.05.001.
Pełny tekst źródłaCui, Lihong, Rongna Wei, Zhiqun Shang i Jing Leng. "Increased expression of high-mobility group A2: A novel independent indicator of poor prognosis in patients with esophageal squamous cell carcinoma". Journal of Cancer Research and Therapeutics 12, nr 4 (2016): 1291. http://dx.doi.org/10.4103/0973-1482.180616.
Pełny tekst źródłaWu, Haijun, Yu Liang, Lin Shen i Liangfang Shen. "MicroRNA-204 modulates colorectal cancer cell sensitivity in response to 5-fluorouracil-based treatment by targeting high mobility group protein A2". Biology Open 5, nr 5 (19.04.2016): 563–70. http://dx.doi.org/10.1242/bio.015008.
Pełny tekst źródłaDiMaio, Christopher J., Frances Weis-Garcia, Emilia Bagiella, Michelle K. Kim, Laura H. Tang i Peter J. Allen. "Tu1217 Pancreatic Cyst Fluid Concentration of High-Mobility Group A2 (HMGA2) Protein Acts As a Differential Biomarker of Dysplasia in IPMN". Gastroenterology 144, nr 5 (maj 2013): S—794—S—795. http://dx.doi.org/10.1016/s0016-5085(13)62933-9.
Pełny tekst źródłaFranco, R., F. Esposito, M. Fedele, G. Liguori, GM Pierantoni, G. Botti, D. Tramontano, A. Fusco i P. Chieffi. "Detection of high-mobility group proteins A1 and A2 represents a valid diagnostic marker in post-pubertal testicular germ cell tumours". Journal of Pathology 214, nr 1 (2007): 58–64. http://dx.doi.org/10.1002/path.2249.
Pełny tekst źródłaMohammadi, Ali, Behzad Mansoori, Pouria Savadi, Vahid khaze, Mahsa Minouei, Nigel A. J. McMillan, Somayeh Hallaj‐Nezhadi i Behzad Baradaran. "Targeting of high mobility group A2 by small interfering RNA‐loaded nanoliposome‐induced apoptosis and migration inhibition in gastrointestinal cancer cells". Journal of Cellular Biochemistry 120, nr 6 (2.12.2018): 9203–12. http://dx.doi.org/10.1002/jcb.28196.
Pełny tekst źródłaRomine, Lorene E., Jennifer R. Wood, LuAnne A. Lamia, Paul Prendergast, Dean P. Edwards i Ann M. Nardulli. "The High Mobility Group Protein 1 Enhances Binding of the Estrogen Receptor DNA Binding Domain to the Estrogen Response Element". Molecular Endocrinology 12, nr 5 (1.05.1998): 664–74. http://dx.doi.org/10.1210/mend.12.5.0111.
Pełny tekst źródłaDiMaio, Christopher J., Frances Weis-Garcia, Emilia Bagiella, Laura H. Tang i Peter J. Allen. "Pancreatic cyst fluid concentration of high-mobility group A2 protein acts as a differential biomarker of dysplasia in intraductal papillary mucinous neoplasm". Gastrointestinal Endoscopy 83, nr 6 (czerwiec 2016): 1205–9. http://dx.doi.org/10.1016/j.gie.2015.09.020.
Pełny tekst źródłaPierantoni, Giovanna Maria, Palma Finelli, Emanuele Valtorta, Daniela Giardino, Ornella Rodeschini, Francesco Esposito, Marco Losa, Alfredo Fusco i Lidia Larizza. "High-mobility group A2 gene expression is frequently induced in non-functioning pituitary adenomas (NFPAs), even in the absence of chromosome 12 polysomy". Endocrine-Related Cancer 12, nr 4 (grudzień 2005): 867–74. http://dx.doi.org/10.1677/erc.1.01049.
Pełny tekst źródłaBorrmann, L. "High mobility group A2 protein and its derivatives bind a specific region of the promoter of DNA repair gene ERCC1 and modulate its activity". Nucleic Acids Research 31, nr 23 (1.12.2003): 6841–51. http://dx.doi.org/10.1093/nar/gkg884.
Pełny tekst źródła